Shots:
- Oscotec has granted Agios exclusive global rights to cevidoplenib (PO), a spleen tyrosine kinase inhibitor, across all indications, incl. immune thrombocytopenia (ITP)
- As per the deal, Agios will assume full development & commercialization costs, while Oscotec will receive $25M upfront, ~$140M in development & regulatory milestones across ~3 indications in the US & EU, plus commercial milestones & tiered royalties ranging from high single digits to mid-teens on net sales
- Oscotec retains an option to obtain exclusive rights to develop and commercialize cevidoplenib in South Korea after P-III results, while Agios plans to initiate P-III development in ITP in H1’28 following additional CMC work
Ref: Globenewswire | Image: Agios & Oscotec | Press Release
Related News: Agios Reports the EC Approval of Pyrukynd for Anemia in Alpha or Beta Thalassemia
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
